“Patients ‘relieved’ by amyloid scans” 

 

MedPage Today

February 8, 2017

Learn more about a recent research study conducted by UCI MIND Co-Director, Dr. Joshua Grill, and colleagues to better understand patient and caregiver reactions to clinical amyloid imaging.

Read more> more >



Research Suggests Space Travel Affects the Brain

U.S. News & World Report
February 6, 2017

“This is not a deal-breaker,” co-author Charles Limoli, a neurobiologist at the University of California, Irvine, said last fall. “I do not think that during the course of a trip to Mars and back the astronauts will come back with anything remotely similar to full-blown Alzheimer’s. more >



Solanezumab fails in Phase 3: What do we know?

December 6, 2016

Joshua Grill, PhD, and Aimee Pierce, MD

screen-shot-2016-12-05-at-9-35-47-amThis week, at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego, we will likely learn more about the recent announcement from Eli Lilly and company that their Phase 3 clinical trial of the monoclonal antibody against the soluble form of beta amyloid, solanezumab, did not demonstrate adequate efficacy to pursue approval from the U.S. more >



UCI MIND featured on KCAL9/CBS2 2 nights in a row

December 1, 2016

KCAL9/CBS2

If you missed UCI MIND Gala Co-Chairs, Lucy &  Roger Lisabeth, on KCAL 9 last night, tune into CBS 2 Los Angeles tonight at 5pm with Elsa Ramon to hear their powerful story.

Learn more about what the Lisabeths and UCI MIND are doing in the fight against Alzheimer’s disease here. more >



Alzheimer’s research at UCI “ramps up”

screen-shot-2016-10-03-at-9-26-54-pm“UCI MIND takes multipronged approach to finding preventions, cures in effort to avert baby-boom crisis…”

 

 

 

 

 

 

 

 

 


  more >



The UCI Consent 2 Contact Registry

c2c-old-manResearch is the key to finding treatments and cures for Alzheimer’s disease and other urgent health problems. If you or someone you know is interested in helping researchers at UCI find cures faster, check out our new online potential participant registry, Consent 2 Contact (C2C) more >



Investigational antibody treatment yields exciting though preliminary results

September 1, 2016
Nature

A paper published August 31 in Nature, describes that Biogen Idec’s candidate treatment, aducanumab, reduced amyloid-β in the brains of patients with early-stage Alzheimer’s disease. Patients receiving the highest doses of the medicine in the Phase IB trial had the largest reductions in brain amyloid and also declined the least in clinical assessments.

more >


Gene Wilder passes away from complications of Alzheimer’s disease

Mandatory Credit: Photo by STEVE WOOD/REX/Shutterstock (74497b) GENE WILDER VARIOUS - 1979

(Steve Wood/Rex/Shutterstock)

August 30, 2016
Huffington Post

We are deeply saddened by the passing of beloved actor Gene Wilder yesterday. His family confirmed Alzheimer’s disease as the cause of death, helping to lift the “veil of stigma about the most common cause of dementia.” more >



University of California announces UCI as a recipient of UC Cures for Alzheimer’s Disease award

ucal-fb-imageUC Office of the President
July 25, 2016

University of California announces UCI team, led by UCI MIND co-director Dr. Joshua Grill, as a recipient of the UC Cures for Alzheimer’s award. Read more…“Joshua Grill, associate professor in the department of psychiatry and human behavior at UC Irvine, will lead a team to study the effects of high doses of vitamin nicotinamide in reducing tau phosphorylation in patients with Alzheimer’s disease…” more >



NASCAR Hall of Famer with dementia pledges to donate his brain

Nell Redmond, AP

Nell Redmond, AP

July 20, 2016

USA Today

“Nearly 45 years after his last Cup race, Lorenzen hoped he would still make his mark on the NASCAR community. Inspired by Dale Earnhardt Jr.’s decision to pledge his brain to the Concussion Legacy Foundation, Lorenzen became the second known driver to make the same decision. more >